Fingerprint
Dive into the research topics of 'Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically